PROZAC POSTS $493.9 MIL. IN THIRD QUARTER U.S. SALES; LILLY SEEKS TO EXPAND MARKET WITH ADOLESCENT DATA; SMITHKLINE PAXIL NINE-MONTH U.S. SALES ARE $477.4 MIL.
• By The Pink Sheet
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
